EDGAR·FLOW

bioAffinity Technologies, Inc. — Form 8-K

Filed November 19, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
bioAffinity Technologies reported 109% year-to-date growth in CyPath Lung test unit sales through Q3 2026, with 89% increase in ordering physicians and 48% growth from repeat customers. The company raised $4M via registered direct offering at market prices in October 2026. New distribution agreement with AvMEDICAL provides access to VA medical centers and federal healthcare facilities nationwide; this partnership does not itself represent completed sales. Company also expanded patent portfolio in Hong Kong, China, and Japan, and is advancing asthma/COPD diagnostic development.
Why this rating

109% test growth and $4M funding are material for $22.6M market-cap company; VA partnership opens significant new channel. Early-stage pipeline risk remains; commercialization trajectory is promising but unproven.

Tradability signal
NO TRADE

No trade: price $0.15 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$0.15
+10 min · unknown
$0.15 ▼ 0.79%
+30 min · unknown
$0.15 ▼ 0.79%
+1 hr · unknown
$0.15 ▼ 0.79%
+4 hrs · unknown
$0.15 ▼ 0.79%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ BIAFW · stock on Yahoo Finance ↗

See more from November 19, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.